Fate TherapeuticsFATE
FATE
About: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Employees: 181
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
133% more call options, than puts
Call options by funds: $91K | Put options by funds: $39K
8% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 48
4% less funds holding
Funds holding: 163 [Q3] → 157 (-6) [Q4]
11.48% less ownership
Funds ownership: 100.66% [Q3] → 89.18% (-11.48%) [Q4]
15% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 40
59% less capital invested
Capital invested by funds: $401M [Q3] → $166M (-$235M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
140%
upside
Avg. target
$4
220%
upside
High target
$5
300%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Stifel Benjamin Burnett 15% 1-year accuracy 2 / 13 met price target | 140%upside $3 | Hold Maintained | 6 Mar 2025 |
Wedbush David Nierengarten 34% 1-year accuracy 40 / 119 met price target | 300%upside $5 | Neutral Reiterated | 6 Mar 2025 |
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target | 220%upside $4 | Equal-Weight Maintained | 6 Mar 2025 |
Financial journalist opinion
Based on 3 articles about FATE published over the past 30 days
Neutral
Zacks Investment Research
6 days ago
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
Neutral
GlobeNewsWire
1 week ago
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process
Neutral
GlobeNewsWire
2 weeks ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
Positive
Zacks Investment Research
1 month ago
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
Negative
Zacks Investment Research
1 month ago
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE
Neutral
GlobeNewsWire
1 month ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
Negative
Zacks Investment Research
2 months ago
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
2 months ago
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:
Positive
Seeking Alpha
2 months ago
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient.
Charts implemented using Lightweight Charts™